A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs Emricasan (Primary)
  • Indications Liver cirrhosis
  • Focus Registrational; Therapeutic Use
  • Acronyms ENCORE-LF
  • Sponsors Conatus Pharmaceuticals
  • Most Recent Events

    • 01 Nov 2017 According to a Conatus Pharmaceuticals media release, top-line results expected in the second half of 2019.
    • 04 May 2017 According to a Conatus Pharmaceuticals media release, top-line results after 48 weeks of twice-daily treatment with emricasan or placebo are expected in 2019.
    • 04 May 2017 Status changed from planning to recruiting, according to a Conatus Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top